{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:56:03Z","timestamp":1775246163171,"version":"3.50.1"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The present randomized, double-blind, placebo-controlled, multicenter clinical trial was designed to compare the efficacy and tolerability of sorivudine [1-\u03b2-\n                    <jats:sc>d<\/jats:sc>\n                    -arabinofuranosyl-E-(2-bromovinyl)uracil] and acyclovir for the treatment of dermatomal herpes zoster in human immunodeficiency virus (HIV)-seropositive patients. A total of 170 HIV-seropositive adults presenting with herpes zoster (confirmed by direct fluorescent-antigen testing and\/or viral culture) were enrolled and randomized to receive a 10-day course of orally administered sorivudine (40 mg once daily plus acyclovir placebos) or acyclovir (800 mg five times daily plus sorivudine placebo). Patients were monitored daily to document the events of cutaneous healing, pain, zoster-related complications, and drug-related adverse events. Patients were reassessed on days 21 and 28 and then once monthly for 1 year. The primary efficacy endpoint was time to the cessation of new vesicle formation. Secondary efficacy endpoints included times to other events of cutaneous healing, resolution of pain, and frequency of dissemination and zoster recurrence. In a multivariate analysis, sorivudine was superior to acyclovir for reducing the times to the cessation of new vesicle formation (relative risk [RR] = 1.54, 95% confidence interval [CI] = 1.00 to 2.36;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.049) and total lesion crusting (RR = 1.48, 95% CI = 1.07 to 2.04;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.017). In a univariate analysis, there was a trend favoring sorivudine for the cessation of new vesicle formation (median of 3 versus 4 days;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.07) and a significant advantage for time to total lesion crusting (median of 7 versus 8 days;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.02). The time to the resolution of zoster-associated pain, the frequency of dissemination, and the frequency of zoster recurrence were not different between the two treatment groups. Both drugs were well tolerated. Sorivudine is an effective drug for the treatment of herpes zoster in HIV-infected patients and results in accelerated cutaneous healing when compared with acyclovir therapy.\n                  <\/jats:p>","DOI":"10.1128\/aac.42.5.1139","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T20:31:56Z","timestamp":1539030716000},"page":"1139-1145","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial"],"prefix":"10.1128","volume":"42","author":[{"suffix":"Jr.","given":"John W.","family":"Gnann","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde S.","family":"Crumpacker","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Beth Israel Deaconess Medical Center, Boston, Massachusetts2;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Lalezari","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Mount Zion Medical Center, San Francisco, California3;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean A.","family":"Smith","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Division of Infectious Diseases, Department of Medicine, University of Texas Health Sciences Center, San Antonio, Texas4;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[{"name":"<!--label omitted: 5-->Department of Microbiology\/Immunology, University of Texas Medical Branch,5 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth F.","family":"Baum","sequence":"additional","affiliation":[{"name":"<!--label omitted: 6-->Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado6;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Borucki","sequence":"additional","affiliation":[{"name":"<!--label omitted: 7-->University of Texas Medical Branch,7 Galveston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Patrick","family":"Joseph","sequence":"additional","affiliation":[{"name":"<!--label omitted: 8-->Infectious Diseases Medical Group, Oakland, California8;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Mertz","sequence":"additional","affiliation":[{"name":"<!--label omitted: 9-->Department of Medicine, Division of Infectious Diseases, University of New Mexico School of Medicine, Albuquerque, New Mexico9;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy T.","family":"Steigbigel","sequence":"additional","affiliation":[{"name":"<!--label omitted: 10-->Division of Infectious Diseases, State University of New York, Stony Brook, New York10; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen A.","family":"Cloud","sequence":"additional","affiliation":[{"name":"<!--label omitted: 11-->Comprehensive Cancer Center,11 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng-jaw","family":"Soong","sequence":"additional","affiliation":[{"name":"<!--label omitted: 12-->Department of Pediatrics, Children\u2019s Hospital,12 University of Alabama at Birmingham, Birmingham, Alabama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanette C.","family":"Sherrill","sequence":"additional","affiliation":[{"name":"<!--label omitted: 11-->Comprehensive Cancer Center,11 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"DeHertogh","sequence":"additional","affiliation":[{"name":"<!--label omitted: 13-->Bristol-Myers Squibb, Princeton, New Jersey13"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Collaborative Antiviral Study Group (Casg)\/aids Clinical Trials Group (Actg) Herpes Zoster Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198306163082404"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/514011"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.5.1153"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.43.1.332-336.1982"},{"key":"e_1_3_3_6_2","first-page":"1094","article-title":"Effect of E-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.","volume":"46","author":"Desgranges C.","year":"1986","unstructured":"Desgranges C. Razaka G. DeClerq E. Herdewijn P. Balzarini J. Drouillet F. Bricaud H. Effect of E-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46 1986 1094 1101","journal-title":"Cancer Res."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.2.370"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.3.524"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Niimura M. A double-blind clinical study in patients with herpes zoster to establish YN-72(Brovavir) dose Immunobiology and prophylaxis of human herpesvirus infections. Lopez C. Mori R. Roizman B. Whitley R. J. 1990 267 275 Plenum Press New York N.Y","DOI":"10.1007\/978-1-4684-5853-4_27"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.1.245"},{"key":"e_1_3_3_12_2","unstructured":"Sherman J. Devault A. Natarajan C. Harkins J. Hedden B. Stouffer B. Whigan D. Kassalow L. Grasela D. Surgerman A. Reilly K. SQ 32 756 (BV-araU): characteristics and pharmacokinetics in healthy young and elderly male volunteers abstr. 1103 Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1990 270 American Society for Microbiology Washington D.C"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Sherman J. L. Kassalow B. J. Harkins B. J. Suites B. Stougger D. Whigan A. A. Shugerman and S. A. Smith. 1990. SQ32 756 (BV-araU): characteristics and pharmacokinetic evaluation in healthy male volunteers. Antivir. Res. 13 (Suppl. 1) : 100.","DOI":"10.1016\/0166-3542(90)90189-E"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.3.576"},{"key":"e_1_3_3_15_2","unstructured":"Sullivan M. Skiest D. Signs D. Young C. the Famciclovir Herpes Zoster in HIV Study Group Famciclovir in the management of acute herpes zoster (HZ) in the HIV-positive patients abstr. 704. Fourth Conference on Retroviruses and Opportunistic Infections 1997"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/369697b0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.2.249"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.3.450"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92139-K"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0026-895X(25)09197-7","article-title":"Mechanism of selective inhibition of varicella-zoster virus replication by 1-beta-d-arabinofuranosyl-E-5-(2-bromovinyl)uracil.","volume":"36","author":"Yokata T.","year":"1989","unstructured":"Yokata T. Kono K. Mori S. Shigeta S. Kumangai M. Watanabe Y. Machida H. Mechanism of selective inhibition of varicella-zoster virus replication by 1-beta-d-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Mol. Pharmacol. 36 1989 312 316","journal-title":"Mol. Pharmacol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.5.1139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.5.1139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:01:32Z","timestamp":1775242892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.5.1139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["10.1128\/AAC.42.5.1139"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.5.1139","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,5]]},"assertion":[{"value":"1997-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}